UnitedHealth’s stock just had its worst day in 9 years

Amy Baxter | | Health Exec | Policy & Regulations
Stocks

UnitedHealth Group saw its worst stock day in nearly 9 years on Feb. 24, with shares dropping 7.8%, according to MarketWatch.

While stocks around the world were dropping the same week due to coronavirus, or Covid-19, fears, investors of UnitedHealth were likely influenced by the Democratic primary results in Nevada at the same time. Sen. Bernie Sanders (I-Vt.), a staunch supporter of a single-payer healthcare system in the U.S., claimed victory among a field of Democratic candidates. Sanders’ policies, if elected, could represent a danger to private healthcare companies and those on Wall Street.

“The manner of his victory in Nevada may have spooked investors,” MarketWatch reported.

However, when Sanders won the New Hampshire Democratic primary in the previous weeks, stock of both Centene and UnitedHealth Group, which owns the nation’s largest health insurance company, rose. Investors at that time more likely believed Sanders would be unable to beat President Trump in the general election.

See the full story below:

UnitedHealth stock suffers worst day in nearly 9 years as Sanders’ Nevada win s…

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
Kentucky AG launches criminal probe after conscious man nearly has organs harvested
FDA announces Class I recall of ventilators after 3 patient injuries
FDA clears AI tool that flags signs of heart disease in chest CT scans
Stewardship Health sale to private equity finalized for $245M
Baxter producing IV solutions ahead of schedule at Asheville-area site

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup